Zhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic

MT Newswires Live

2025/02/27

Zhejiang Medicine (SHA:600216) subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.

The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.

Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.

Shares of the drug company closed 2% higher Thursday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514582033"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514582033\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514582033?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514582033","market":"hk","top_or_hot":-1,"title":"Zhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic","media":"MT Newswires Live","content":"<html><body><p> Zhejiang Medicine (SHA:600216) subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.</p><p>The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.</p><p>Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.</p><p>Shares of the drug company closed 2% higher Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-27 16:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zhejiang Medicine (SHA:600216) subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.</p><p>The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.</p><p>Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.</p><p>Shares of the drug company closed 2% higher Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600216","symbol_name":"浙江医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514582033","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514582033","pubTimestamp":1740646703,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhejiang Medicine  subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.Shares of the drug company closed 2% higher Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600216":"浙江医药","BK0028":"国家队","BK0239":"医药制造","BK0191":"维生素","BK0188":"融资融券"},"translate_title":"浙江医药子公司抗生素通过美国FDA检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600216":0.9},"content_text":"Zhejiang Medicine (SHA:600216) subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.Shares of the drug company closed 2% higher Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}